RT @synovialjoints: Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during ta
Tweet Content
Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl
Show on Archive Page
On
Display in Search Results
On
PDQ
Off